Analyst firms · Morgan Stanley · ABMD
Morgan Stanley ABMD price target and rating history
ABIOMED Inc. (ABMD) · Health Care
Morgan Stanley rates ABIOMED Inc. (ABMD) Equal-Weight with a $380 price target, as of its latest action on Nov 2, 2022. It has published 3 rating actions on ABMD since January 2022, including 1 upgrade and 0 downgrades.
- Current rating
- Equal-Weight
- Price target
- $380
- Median target, all firms
- Too few
- Actions on ABMD
- 3
Morgan Stanley price target on ABMD
Every Morgan Stanley rating on ABMD
- Nov 2, 2022
- Feb 4, 2022
- Jan 7, 2022
Questions about Morgan Stanley and ABMD
- What is Morgan Stanley's price target for ABMD?
- Morgan Stanley's latest stated price target for ABIOMED Inc. (ABMD) is $380, from its action on Nov 2, 2022.
- What is Morgan Stanley's rating on ABMD?
- Morgan Stanley rates ABMD Equal-Weight, a neutral rating, as of Nov 2, 2022.
- When did Morgan Stanley last change its view on ABMD?
- On Nov 2, 2022, Morgan Stanley upgrades to Equal-Weight from Underweight, price target $235 to $380.
More ABMD rating histories
All Morgan Stanley ratingsABMD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.